"Designing Growth Strategies is in our DNA"
The global critical care antiarrhythmic drugs market size was USD 796.8 million in 2019 and is projected to grow from USD 899.8 million in 2020 to USD 1,319.7 million by 2027, exhibiting a CAGR of 5.6% in the 2020-2027 period. Based on our analysis, the global market will exhibit a stellar growth of 12.9% in 2020. The global impact of COVID-19 has been unprecedented and staggering, with critical care antiarrhythmic drugs witnessing a positive demand shock across all regions amid the pandemic.
The increasing prevalence of cardiovascular disorders across the globe will strongly propel market growth. According to a study published by the American Heart Association (AHA), cardiac disorders are the leading cause of death, accounting for more than 17.6 million deaths in 2016 and more than 23.6 million expected deaths by 2030 globally. Cardiovascular disorders (CVD) and stroke accounted for 14.0% of the total health expenditures in 2014-2015. This is one of the major factors augmenting the critical care antiarrhythmic drugs market growth during the projected timeframe.
Cardiovascular disorders such as atrial fibrillation (AFib) are one of the major conditions leading to irregular heartbeats, referred to as arrhythmia. Hence, the growing incidence of the disorder across the globe will strongly propel market expansion. AFib is the most common arrhythmia diagnosed in clinical practice. For instance, as per the National Center for Chronic Disease Prevention and Health Promotion, it is estimated that 12.1 million people in the U.S. will have AFib by 2030. Also, in 2018, AFib accounted for 175,326 deaths across the U.S. Such factors are responsible for boosting the demand for critical care antiarrhythmic drugs.
Surge in COVID-19 Cases Increases the Risk of Recurrent Cardiac Arrhythmias in Critically Ill COVID Patients
It was originally thought that the novel coronavirus (COVID-19, SARS-CoV-2) was primarily a respiratory disorder, but as larger numbers of patients contracted the virus, many physiological manifestations of the disease are coming to the fore. The impact of COVID-19 goes well beyond the lungs to impact the cardiovascular system and cause complications, such as stroke, shock, heart failure, myocarditis, and arrhythmias.
As Covid-19 cases surge across the globe, the risk of recurrent cardiac arrhythmias in critically ill COVID-19 patients is also high. However, the arrhythmias may stem from cardiac complications and may not be caused by the virus alone. For instance, a study published by the Journal of the American Medical Association (JAMA) states that, in February 2020, 44.4% of the patients assessed from China, Wuhan was treated in intensive care units due to complications related to arrhythmias. Arrhythmias may also be aggravated by severe systemic inflammatory conditions associated with COVID-19. Hence, this factor is likely to have a positive impact on the growth of the critical care antiarrhythmogenic drugs market amidst the pandemic.
Request a Free sample to learn more about this report.
Increasing Number of Clinical Trials Pertaining to Novel Anti-Arrhythmia Therapeutics is a Prominent Market Trend
The increasing number of new trials conducted recently for treating arrhythmias show improved outcomes and lower rates of hospitalization for patients with novel drug solutions. These clinical trials are being initiated to develop an effective therapeutic framework for atrial fibrillation drug development. For instance, in August 2020, a pilot and feasibility study was conducted at the Vanderbilt University Medical Center (U.S.), where the enrolled patients with frequent symptomatic episodes of atrial fibrillation were observed and analyzed in a cross-over study testing two different classes of antiarrhythmic drugs (AADs). This study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common atrial fibrillation genetic risk allele modulates response to different AADs.
Rising Adoption of Antiarrhythmic Drugs in Intensive Care Units (ICUs) Will Support Market Growth
One of the major factors supporting the growth of the critical care antiarrhythmic drugs market is the growing adoption of these therapeutics in intensive care units for the treatment of patients with acute arrhythmias. As per the National Center for Biotechnology Information (NCBI), atrial fibrillation is frequently observed in medical intensive care units (MICU), with up to 30% of MICU patients showing periods of atrial fibrillation. Cardiac arrhythmias are a common complication in ICUs, with reported rates as high as 40%. Many of the common disorder states seen in critically ill patients, including cardiac and pulmonary disease, are risk factors for the development of arrhythmias, making recognition and management in the ICU vitally important. This is one of the most prominent factors expected to augment market growth across the forecast period.
Side Effects Associated with Antiarrhythmic Drugs Might Restrict Market Growth
Adverse effects associated with antiarrhythmic drugs might act as a growth hampering factor for the market. Quinidine, procainamide, mexiletine, flecainide, and propafenone are all class I antiarrhythmic drugs used for the treatment of various atrial and ventricular arrhythmias.
Despite the benefits of these drugs, there are certain side effects associated with the use of antiarrhythmic medications, such as cardiovascular toxicity, central nervous system toxicity, gastrointestinal symptoms, immune-mediated reactions, and few others. As a result, these undesirable effects may significantly restrict market potential.
To know how our report can help streamline your business, Speak to Analyst
Beta Blockers Segment to Dominate Supported by Growing Applications
Based on Drug Class, the global market is categorized into beta blockers, calcium channel blockers, sodium channel blockers, potassium channel blockers, and others.
Among them, the beta-blockers segment held the major market share in 2019. The segment’s dominant share is attributable to the fact that a growing number of research trials are being conducted across the globe to evaluate the efficacy of these drugs in treating arrhythmias. For instance, in November 2016, GlaxoSmithKline announced the initiation of a research study for the evaluation of the efficacy and safety of Lovaza (Omega-3-Acid Ethyl Esters) beta blocker in recurrent, symptomatic atrial fibrillation.
The potassium channel blockers segment, on the other hand, is estimated to witness lucrative growth over the forecast period. This is due to the fact that these drugs are highly effective in treating atrial fibrillation and related arrhythmias. The increasing investments in research and development activities for the development of novel biologics will support the growth of the market in the coming years.
Supraventricular Arrhythmias Segment to Hold Largest Market Share
In terms of disease type, the supraventricular arrhythmias segment held the leading market share in 2019. The high share of the segment is majorly supported by the growing prevalence of the condition across the globe. For instance, according to data from the World Health Organization (WHO), as of 2018, atrial fibrillation and atrial flutter were the most common subtypes of supraventricular arrhythmias, affecting approximately 6 million patients in the U.S.
The ventricular arrhythmias segment held a considerable market share in 2019. The segment is poised to experience a positive growth trajectory during the forecast period, owing to the increasing number of cases of the disorder worldwide. Moreover, with the increasing prevalence of the disorder, the demand for biologics pertaining to ventricular arrhythmias has spiked, thereby augmenting segmental growth.
North America Critical Care Antiarrhythmic Drugs Market Size, 2019 (USD Million)
To get more information on the regional analysis of this market, Request a Free sample
The market size in North America stood at USD 359.2 million in 2019. The increasing number of clinical trials pertaining to the development of novel antiarrhythmic drugs, especially in the U.S., is one of the major growth propelling factors. Moreover, the growing number of drug launches across the region will further support the regional expansion of the critical care antiarrhythmic drugs market. For instance, in June 2016, Mylan N.V. announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol SR, which is indicated to prolong the time for the recurrence of symptomatic atrial fibrillation (AF) in patients with episodic AF who do not have structural heart disease.
Europe is projected to be the second-largest region in terms of market share and revenue. This is attributable to the rapidly rising geriatric population, along with an increasing number of cardiac issues, a large number of manufacturers, and favorable reimbursement policies.
The market in Asia Pacific is likely to expand at a significantly high growth rate. The rising number of government initiatives to raise awareness among the population about the ill effects of prolonged atrial fibrillation is strongly supporting the regional growth of the market.
Increasing healthcare spending, growing penetration of market players, and a rising number of pilot studies being conducted in the region to evaluate the access to arrhythmia drug treatment among patients are the factors propelling market growth in Latin America and the Middle East & Africa.
Sanofi, Pfizer, and Mylan N.V. to Dominate Supported by Increasing Number of Strategic Partnerships
The critical care anti-arrhythmic drugs market is considerably consolidated in nature, with major players, such as Sanofi, Pfizer, Mylan N.V., etc., accounting for a major portion in the industry. Sanofi was the dominant player operating in the antiarrhythmic drugs industry in 2019. The company has been continuously holding a strong position in the cardiovascular drugs industry. This is attributable to several factors, such as novel biologics launches, a robust distribution network across the globe, and a strong focus on mergers and partnerships with major pharmaceutical organizations. For instance, in February 2018, AnaBios announced a partnership with Sanofi to develop a new treatment for atrial fibrillation. The program will focus on compounds designed to modulate a novel cardiac ion channel target.
An Infographic Representation of Critical Care Antiarrhythmic Drugs Market
To get information on various segments, share your queries with us
The critical care antiarrhythmic drugs market research report provides a detailed analysis of the market and focuses on key aspects, such as leading companies, drug classes, and disease types. Besides this, it offers insights into the current market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market over recent years.
Value (USD million)
By Drug Class
By Disease Type
Fortune Business Insights says that the global critical care antiarrhythmic drugs market size stood at USD 796.8 million in 2019 and is projected to reach USD 1,319.7 million by 2027.
In 2019, the market value stood at USD 796.8 million.
The market will exhibit decent growth at a CAGR of 5.6% during the forecast period (2020-2027).
By drug class, the beta blockers segment will be the leading segment in the market.
The increasing prevalence of cardiac disorders, the growing number of clinical trials, rising geriatric populations, and a high willingness to spend on anti-arrhythmia drug research are the key drivers of the market.
Sanofi, Pfizer, and Mylan N.V. are the top players in the market.
“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”- U.S.-based biotechnology company focussing on treatment of chronic pain.
“Kudos to your team. Thank you very much for your support and agility to answer our questions.”- Europe-based provider of solutions to automate data centre operations.
“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”- India-based manufacturer of industrial and specialty intermediates with a strong global presence.
“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”- One of the largest cosmetics company in the world.
“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”- U.S. based startup operating in the cultivated meat market.
“We received the below report on the U.S. market from you. We were very satisfied with the report.”- UGlobal hearing aids manufacturer.
“I just finished my first pass-through of the report. Great work! Thank you!”- U.S. based solar racking solutions provider.
“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”- World’s leading advisory firm.
“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”- Germany based machine construction company.
“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”- Japanese manufacturing company of stationery products.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry